Insilico Medicine and SK Biopharmaceuticals announced a collaboration at BIO 2026 that could total more than $2.5 billion, aiming to accelerate discovery of therapeutics for neuroimmune disorders in the CNS. Insilico will apply its Pharma.AI platform for target discovery and candidate design, while SK Biopharmaceuticals will lead late-stage development and commercialization. The deal structure includes $18 million in upfront and near-term milestone payments, with additional value tied to development, regulatory, and commercial achievements. The program is designed to leverage Insilico’s AI-driven target-to-candidate engine and SK’s CNS development and expertise. The announcement reflects how AI-first discovery models are increasingly being packaged into large, milestone-driven BD transactions, as drugmakers seek speed-to-candidate while outsourcing early discovery risk. It also reinforces SK Biopharmaceuticals’ expansion beyond epilepsy into broader neurodegenerative and neuroinflammatory indications. For the biotech ecosystem, the key implication is whether AI-enabled target generation translates into clinical candidates with credible differentiation—especially in neuroimmune disease, where target biology and patient stratification are often complex.